Abstract
Objectives The prognostic value of pentraxin 3 (PTX3) has been documented in patients with acute coronary syndrome. However, its long-term prognostic value in acute ST-segment elevation myocardial infarction (STEMI) remains unclear. The aim of this study was to evaluate the prognostic value of PTX3 in patients with STEMI undergoing a primary percutaneous coronary intervention (PCI).,Methods We prospectively enrolled 499 consecutive STEMI patients undergoing primary PCI. The high-PTX3 group (n = 141) was defined as having values in the third tertile (>= 3.2 ng/ml) and the low-PTX3 group (n = 358) included patients with values in the lower two tertiles (< 3.2 ng/ml).,Results The patients in the high-PTX3 group were older (mean age 54.3 +/- 11.8 vs. 58.5 +/- 13.1 years, P = 0.002). Higher in-hospital cardiovascular mortality and 2-year all-cause mortality rates were observed in the high-PTX3 group (9.9 vs. 2.8%, respectively, P < 0.001; 21 vs. 6.2%, respectively, P < 0.001). In a Cox multivariate analysis, a high admission PTX3 value (> 3.2 ng/ml) was found to be an independent predictor of 2-year all-cause mortality (odds ratio: 2.3, 95% confidence interval: 1.20-4.90, P = 0.025).,Conclusion These results suggest that a high admission PTX3 level was associated with increased in-hospital cardiovascular mortality and 2-year all-cause mortality in patients with STEMI undergoing primary PCI. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.
-
Kapsamı
Uluslararası
-
Type
Hakemli
-
Index info
WOS.SCI
-
Language
English
-
Article Type
None